Subscribe Now
  • Home
  • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Coins2Day 500
    • Coins2Day 500 U.S.
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
  • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  • Home
  • Latest
    • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Coins2Day 500
    • Coins2Day 500
    • Coins2Day 500 U.S.
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
  • Finance
    • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  1. home
  1. home
  2. Pershing Square

Pershing Square

Page 4 of 5

Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Finance

Bill Ackman Hints Who Valeant’s Next CEO Will Be

By Jen Wieczner
April 6, 2016
Hedge fund manager Bill Ackman
Finance

Ackman Sells Big Mondelez Stake Amid Major Losses

By Reuters
March 16, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Leadership

Valeant to Walgreens: Hey, It’s Not Your Fault After All

By Jennifer Reingold
March 16, 2016
Nearly Every Stock Bill Ackman Owns Is Down This Year
Finance

Nearly Every Stock Bill Ackman Owns Is Down This Year

By Stephen Gandel
March 15, 2016
Key Speakers At The Bloomberg Markets Most Influential Summit
Finance

Bill Ackman Is Running Out of Options with Valeant

By Stephen Gandel
March 15, 2016
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Health

Bill Ackman Just Got Himself a Board Member on Valeant

By Reuters
March 9, 2016
Ackman, founder and CEO of hedge fund Pershing Square Capital Management, speaks at the Sohn Investment Conference in New York
Finance

Bill Ackman to World: Not my Fault

By Jennifer Reingold
January 28, 2016
Key Speakers At The Bloomberg Markets Most Influential Summit
Finance

Hedge Fund Billionaire Bill Ackman Admits He Made Mistakes

By Reuters
January 27, 2016
Hedge fund manager Bill Ackman
Finance

Another one of Bill Ackman’s top stocks is down 50%

By Jen Wieczner
October 29, 2015
2 piastres coin
Finance

Herbalife activist investor Bill Ackman’s unprecedented catalytic crusade

By Robert Hackett
September 9, 2015
Icahn Enterprises L.P. To Ring The NASDAQ Stock Market Closing Bell
Leadership

Why activist investors are getting even more…active

By Paul Hodgson
December 3, 2014
Botox
Finance

Actavis agrees to buy Botox-maker Allergan for $66 billion

By John Kell
November 17, 2014
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Finance

Bill Ackman confirms Pershing Square Holdings IPO plan

By Tom Huddleston Jr.
August 13, 2014
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
Finance

Bill Ackman’s crusade against Herbalife is running out of time

By Laura Lorenzetti
July 23, 2014
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview

Ackman’s Herbalife ‘death blow’ doesn’t appear to be fatal

By Laura Lorenzetti
July 22, 2014

Most Popular

  • AI
    Elon Musk says that in 10 to 20 years, work will be optional and money will be irrelevant thanks to AI and robotics
    By Sasha Rogelberg
  • Personal Finance
    Current price of silver as of Tuesday, January 20, 2026
    By Joseph Hostetler
  • Economy
    Trump added $2.25 trillion to the national debt in his first year back in charge, watchdog says
    By Nick Lichtenberg
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Coins2Day
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.